Design Therapeutics, Inc. (DSGN) Financial Statements
Design Therapeutics, Inc. (DSGN) reported trailing twelve-month revenue of $0 (up 0.0% year on year) and net income of -$70.8M as of 2026-06-30, according to EquiReason's reading of its SEC filings. Free cash flow over the same period: -$55.1M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
DSGNDesign Therapeutics, Inc.Follow DSGN — free
—
Price chart with a free account
- Market cap
- 640.8M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 11 Nov, in 17 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | 0.0 | |
| Research & development | 24.8 | 48.6 | 57.1 | 44.4 | 59.1 | 58.8 | |
| Operating income | -35.8 | -67.6 | -78.2 | -62.4 | -79.5 | -79.4 | |
| Pre-tax income | -35.5 | -63.3 | -66.9 | -49.6 | -69.8 | -70.8 | |
| Income tax | — | — | — | — | 0.0 | — | |
| Net income | -35.5 | -63.3 | -66.9 | -49.6 | -69.8 | -70.8 | |
| Diluted EPS ($) | -0.77 | -1.14 | -1.19 | -0.88 | -1.22 | -1.18 | |
| Diluted shares (mn) | — | 55.7 | 56.0 | 56.6 | 57.3 | — |
USD millions · SEC XBRL
Design Therapeutics, Inc. — questions
- What is Design Therapeutics, Inc.'s revenue?
- $0 over the twelve months to 2026-06-30, up 0.0% year on year, from its 10-Q and 10-K filings.
- What is Design Therapeutics, Inc.'s net income?
- -$70.8M over the twelve months to 2026-06-30.
- What is Design Therapeutics, Inc.'s free cash flow?
- -$55.1M over the twelve months to 2026-06-30.
- What are Design Therapeutics, Inc.'s diluted earnings per share?
- $-1.18 over the twelve months to 2026-06-30.
Every figure on this page comes from Design Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.